On June 17th, 2022, Global Regulatory Partner Inc. through its subsidiary in Mexico submitted to the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health authority in Mexico, seeking the approval of the freeze-dried version of smallpox vaccine.
The vaccine has an improved shelf-life and storage conditions to replace the stockpile of the previous liquid-frozen version. The vaccine is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
about global regulatory partners
Global Regulatory Partners, Inc (GRP) is a global provider of tailored clinical development, regulatory affairs, quality and pharmacovigilance services for pharma, biotech, medical devices and cosmetic industries worldwide.
Global Regulatory Partners. Inc, has now over 500 employees, 6 affiliates in 6 countries (USA, Brazil, Mexico, Japan, China and South Korea) and more than 500 satisfied clients worldwide.
In China, GRP-China has offices in three locations, Shanghai, Beijing and Hainan, and has local teams of Regulatory Affairs, Clinical Development ,Quality and Pharmacovigilance professionals, who support the clinical development and products’ registration of many pharmaceutical and medical device companies in Hainan pilot zone and in China Mainland as well.